Literature DB >> 26090488

Interleukin-23R rs7517847 T/G Polymorphism Contributes to the Risk of Crohn's Disease in Caucasians: A Meta-Analysis.

Li Zhang1, Yunjie Lu2, Yuzheng Ge3, Yun Shi1, Xing Wu1, Qinghua Xu1, Xiaoping Li1, Ling Lu2, Feng Zhang2, Guozhong Yao1.   

Abstract

The association between Interleukin-23R gene polymorphism and Crohn's disease (CD) in Caucasians is still controversial. Thus, a meta-analysis was performed to evaluate the correlation between this gene variant and CD risk. We retrieved the available data from EMBASE and PUBMED until May 1, 2014, and evaluated the effect of rs7517847 in Caucasians. The significant associations were confirmed between rs7517847 and CD risk in dominant models (TT/TG versus GG: OR = 1.652, 95% CI 1.277, 2.137), allelic model (T allele versus G allele: OR = 1.327, 95% CI 1.198, 1.469), homozygote comparison (TT versus GG: OR = 1.890, 95% CI 1.465, 2.437), heterozygote comparison (TG versus GG: OR = 1.509, 95% CI 1.161, 1.960), and recessive model (TT versus TG/GG: OR = 1.409, 95% CI 1.279, 1.552). In conclusion, this meta-analysis demonstrates that rs7517847 is associated with the risk of CD in Caucasians. These findings show that IL-23R genes confer susceptibility to CD in the Caucasians.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26090488      PMCID: PMC4451526          DOI: 10.1155/2015/279849

Source DB:  PubMed          Journal:  J Immunol Res        ISSN: 2314-7156            Impact factor:   4.818


1. Introduction

Crohn's disease (CD) is a form of inflammatory bowel disease (IBD) that primarily affects the Caucasian population [1, 2]. It is a heritable disease which is influenced by many genetic risk factors [3]. Therefore, identification of gene risk factors of CD is beneficial for the clinical treatment of patients. Interleukin 23 (IL-23) plays an important role in the inflammatory response against infection as a regulator of immune cells [4]. IL-23R which interacts with IL-23 is a protein consisting of an IL-12β1 and an IL-23R chain [5]. Recently, the mechanisms of IL-23R variants have been investigated in different autoimmune diseases [6-9]. Studies also have shown that rs7517847, the single nucleotide polymorphisms (SNPs) of the IL23R gene, are associated with CD occurring rate [10, 11]. However, the association between IL-23R polymorphisms and CD susceptibility are inconclusive and controversial due to small sample size in each of the published studies. To better understand the association of IL-23R polymorphisms and CD susceptibility in Caucasians, we conducted a meta-analysis of all eligible studies and hope to yield more accurate and robust estimates.

2. Materials and Methods

2.1. Search Strategy

We searched for relevant studies in the following databases: EMBASE and PUBMED. Available studies for IL-23R polymorphism and CD were collected by different combinations of various key words: Interleukin-23 receptor, IL-23R; polymorphism, variant, or mutation; Crohn's disease, CD. Languages restriction was not imposed in this research and only published studies with full text were included in this meta-analysis.

2.2. Inclusion and Exclusion Criteria of Trials

In the meta-analysis, the following inclusive selection criteria were set: (a) study design evaluating the association between IL-23R polymorphism and CD risk; (b) case control design; (c) Caucasians design. The following exclusive selection criteria were set: (a) no control cases; (b) duplication of the previous publication; (c) no available genotype frequency; for studies with overlapped or repeated data (d) no Caucasians.

2.3. Data Extraction

Eligible studies were extracted by 2 reviewers (Li Zhang and Yunjie Lu) independently according to the predesigned data collection form. The following information was extracted: first author's name, publication year, country, ethnicity, immune suppressive protocol, number of cases and controls, and genotype distribution in both groups. Disagreement was resolved by discussion with a third reviewer (Guozhong Yao).

2.4. Statistical Analysis

For each trial, odds ratio (OR) with the 95% confidence interval (95% CI) of the survival rate was derived and calculated. Increased or decreased risk of CD was indicated by 95% CI without 1 for OR. The pooled ORs were estimated for allelic model (T allele versus G allele), homozygote comparison (TT versus GG) and heterozygote comparison (TG versus GG), dominant models (TT/TG versus GG), and recessive model (TT versus TG+GG). Z test was performed to assess the significance of the pooled OR. Between-study heterogeneity was assessed by the Cochran's Q statistic and I 2 tests [12]. The random effects model was conducted if the Q test exhibited a P < 0.05 or the I 2 test showed >50%. Otherwise, the fixed effects model would be conducted. For publication bias, the Begg's funnel plot and Egger's linear regression test were conducted, and P < 0.05 was considered significant. A fixed-effect model (based on Mantel-Haenszel method) was utilized to pool the data from different studies if the between-study heterogeneity was absent, or a random-effect model (based on DerSimonian and Laird method) was applied. The statistical analysis was performed by STATA 10.0 (Stata Corp LP, College Station, TX, USA). All P values are two-side.

3. Results

3.1. Selection of the Included Studies and Characteristics

The flow diagram of studies selection and exclusion reasons were represented in Figure 1. A total of 133 studies were identified by our first research; a number of 41 were preliminarily yielded out after excluding inappropriate studies and screening abstract-screening, full-text assessment. In these 41 studies, 30 were excluded, 11 articles containing rs7517847 in Caucasians were recruited for detailed analysis (Table 1), and these data built Table 1 [13-23]. Each of them was independent. Thus, a total of 3279 CD cases and 4136 healthy controls were included in our meta-analysis. All of them were Caucasian and the diagnosis of CD was based on clinical manifestations and laboratory examinations and further biopsy.
Figure 1

Flow diagram of the study selection process and specific reasons for exclusion.

Table 1

Characteristics of eligible studies included in the meta-analysis.

AuthorYearCountryEthnicityGenotyping methodsCaseControlHWE
TTTGGGTTTGGG
Safrany et al. [13]2013HungaryCaucasianPCR–RFLP721101774138410.081
Szabo et al. [14]2013HungaryCaucasianPCR–RFLP150182645799260.104
Ferguson et al. [15]2010New ZealandCaucasianMassARRAY10817229113183720.892
Lauriola et al. [16]2011ItalyCaucasianPCR94613610.78
Lacher et al. [17]2010GermanyCaucasianRT-PCR811013978125500.995
Latiano et al. [18]2008ItalyCaucasianPCR-RFLP366305522803281080.459
Márquez et al. [19]2008SpainCaucasianRT-PCR14516136192260940.71
Baptista et al. [20]2008BrazilCaucasianRT-PCR59952879120430.825
Newman et al. [21]2009EnglandCaucasianMassARRAY195204403004361640.799
Okazaki et al. [22]2008CanadaCaucasianRT-PCR84913691157660.91
Oliver et al. [23]2007SpainCaucasianTaqman PCR10111918121153680.124

3.2. Evaluation of the Association

The OR from all models indicated a significant association between rs7517847 and CD. After pooling all the eligible studies in Table 2, we found that the risk of CD was significantly associated with rs7517847 in dominant models (TT/TG versus GG: OR = 1.652, 95% CI 1.277, 2.137), allelic model (T allele versus G allele: OR = 1.327, 95% CI 1.198, 1.469), homozygote comparison (TT versus GG: OR = 1.890, 95% CI 1.465, 2.437, Figure 2), heterozygote comparison (TG versus GG: OR = 1.509, 95% CI 1.161, 1.960), and recessive model (TT versus TG/GG: OR = 1.409, 95% CI 1.279, 1.552). These data demonstrate that rs7517847 increases the risk of CD among Caucasians with hospital-based studies.
Table 2

Stratified analysis of rs7517847 polymorphism and CD risk in eligible studies.

AuthorYearT versus G alleleTT versus GG OR (95% CI)TG versus GG OR (95% CI)TT + TG versus GG (95% CI)TT versus TG + GG (95% CI)
Total 1.327 (1.198, 1.469) 1.890 (1.465, 2.437) 1.509 (1.161, 1.960) 1.652 (1.277, 2.137) 1.409 (1.279, 1.552)
Safrany et al. [13]20131.357 (1.036, 1.777)2.347 (1.223, 4.503)1.922 (1.036, 3.568)2.070 (1.137, 3.769)1.371 (0.923, 2.038)
Szabo et al. [14]20131.102 (0.856, 1.419)1.069 (0.618, 1.850)0.747 (0.445, 1.253)0.865 (0.528, 1.417)1.337 (0.921, 1.942)
Ferguson et al. [15]20101.349 (1.084, 1.678)2.373 (1.432, 3.933)2.334 (1.446, 3.766)2.349 (1.481, 3.724)1.213 (0.879, 1.673)
Lauriola et al. [16]20110.344 (0.126, 0.941)0.115 (0.012, 1.129)0.111 (0.009, 1.309)0.114 (0.012, 1.062)0.485 (0.134, 1.754)
Lacher et al. [17]20101.176 (0.908, 1.523)1.331 (0.790, 2.243)1.036 (0.632, 1.698)1.149 (0.723, 1.828)1.298 (0.886, 1.902)
Latiano et al. [18]20081.553 (1.328, 1.816)2.715 (1.884, 3.913)1.931 (1.340, 2.784)2.292 (1.618, 3.248)1.596 (1.295, 1.968)
Márquez et al. [19]20081.347 (1.104, 1.643)1.972 (1.269, 3.063)1.617 (1.050, 2.489)1.768 (1.172, 2.665)1.357 (1.029, 1.791)
Baptista et al. [20]20081.045 (0.793, 1.377)1.147 (0.640, 2.055)1.216 (0.704, 2.100)1.188 (0.706, 2.000)0.990 (0.656, 1.492)
Newman et al. [21]20091.542 (1.302, 1.827)2.665 (1.805, 3.935)1.918 (1.307, 2.815)2.223 (1.541, 3.207)1.598 (1.265, 2.019)
Okazaki et al. [22]20081.355 (1.054, 1.741)1.692 (1.024, 2.798)1.918 (1.307, 2.815)1.294 (0.825, 2.029)1.621 (1.122, 2.342)
Oliver et al. [23]20071.515 (1.187, 1.935)3.153 (1.761, 5.648)2.938 (1.658, 5.207)3.033 (1.752, 5.252)1.347 (0.959, 1.891)
Figure 2

Forest plot for risk of CD associated with rs7517847 in Caucasian (TT versus GG. For each study, the estimate of OR and its 95% CI is plotted with a box and a horizontal line. Filled diamond pooled OR and its 95% CI).

3.3. Publication Bias

Begg's funnel plot and Egger's test were both performed to assess the publication bias of this meta-analysis. The shape of the funnel plots for homozygote comparison models seemed symmetrical (Figure 3). Then, the Egger's test was used to provide statistical evidence of funnel plot symmetry. The results still did not suggest any evidence of publication bias. Thus, publication bias was not evident in present meta-analyses.
Figure 3

Begg's funnel plot for publication bias test (TT versus GG for rs7517847).

4. Discussion

CD is associated with JAK2 signaling pathway which is activated by IL-23 and IL-23R receptor [24]. Previous studies suggested that the interruption of IL-23R SNPs might lead to the dysregulation of intestinal inflammation [25]. IL-23R gene variants also play an essential role in the development of many autoimmune diseases such as ankylosing spondylitis (AS), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE) [7, 26, 27]. Therefore, researchers are focusing on observing the relationship between IL-23R gene polymorphisms and the risk of CD. However, the results are conflicting and controversial due to the different races and insufficient sample size. After pooling data for 11 studies in this meta-analysis, our results firstly demonstrate that T allele of rs7517847 was highly susceptible to CD in Caucasians. One previous study showed that rs7517847 is a protective factor in rheumatoid arthritis (RA) in European population. Interestingly, RA is a systemic autoinflammatory disease which is associated with PTPN22/C1858T, while the organ-specific autoimmune disease CD is not [28, 29]. Thus, the mechanism of this genetic variant may not play a common role in different autoimmune diseases. More researches are required to observe the exact mechanisms of IL-23R gene polymorphism. We should also mention the limitations of this meta-analysis. Primarily, all the studies were limited to the Caucasian. The allelic frequencies may be different in other ethnic groups. Secondly, publication bias might occur even if there is no significance in statistical test due to extracting published studies. Ultimately, owing to methodological limitations, this meta-analysis is retrospective. Two independent authors performed the process of study selection and data extraction and a third author resolved the discrepancy to minimize the bias. In conclusion, our meta-analysis suggests that IL-23R rs7517847 confers susceptibility to CD in the Caucasians. Furthermore, more studies with larger scale are required to confirm these associations.
  29 in total

1.  Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production.

Authors:  Antonie Zwiers; Laurens Kraal; Tineke C T M van de Pouw Kraan; Thomas Wurdinger; Gerd Bouma; Georg Kraal
Journal:  J Immunol       Date:  2012-01-18       Impact factor: 5.422

2.  Replication of an association between IL23R gene polymorphism with inflammatory bowel disease.

Authors:  Javier Oliver; Blanca Rueda; Miguel A López-Nevot; María Gómez-García; Javier Martín
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08       Impact factor: 11.382

3.  A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.

Authors:  Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho
Journal:  Science       Date:  2006-10-26       Impact factor: 47.728

4.  Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions.

Authors:  Toshihiko Okazaki; Ming-Hsi Wang; Patricia Rawsthorne; Michael Sargent; Lisa Wu Datta; Yin Yao Shugart; Charles N Bernstein; Steven R Brant
Journal:  Inflamm Bowel Dis       Date:  2008-11       Impact factor: 5.325

5.  IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes.

Authors:  Mattia Lauriola; Giampaolo Ugolini; Stefano Rivetti; Sara Nanì; Giancarlo Rosati; Simone Zanotti; Isacco Montroni; Alessio Manaresi; Davide Zattoni; Andrea Belluzzi; Lucia Castellani; Gabriele D'Uva; Gabriella Mattei; Mario Taffurelli; Pierluigi Strippoli; Rossella Solmi
Journal:  Int J Mol Med       Date:  2010-12-27       Impact factor: 4.101

Review 6.  The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.

Authors:  Y H Lee; Y H Rho; S J Choi; J D Ji; G G Song; S K Nath; J B Harley
Journal:  Rheumatology (Oxford)       Date:  2006-06-07       Impact factor: 7.580

7.  Difference of interleukin-23 receptor gene haplotype variants in ulcerative colitis compared to Crohn's disease and psoriasis.

Authors:  Eniko Safrany; Melinda Szabo; Marta Szell; Lajos Kemeny; Katalin Sumegi; Bela I Melegh; Lili Magyari; Petra Matyas; Maria Figler; Agnes Weber; Zsolt Tulassay; Bela Melegh
Journal:  Inflamm Res       Date:  2012-10-25       Impact factor: 4.575

8.  Interaction of Crohn's disease susceptibility genes in an Australian paediatric cohort.

Authors:  Josef Wagner; Winnie H Sim; Justine A Ellis; Eng K Ong; Anthony G Catto-Smith; Donald J S Cameron; Ruth F Bishop; Carl D Kirkwood
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

9.  Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy.

Authors:  Anna Latiano; Orazio Palmieri; Maria Rosa Valvano; Renata D'Incà; Salvatore Cucchiara; Gabriele Riegler; Anna Maria Staiano; Sandro Ardizzone; Salvatore Accomando; Gian Luigi de Angelis; Giuseppe Corritore; Fabrizio Bossa; Vito Annese
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 10.  The genetics of Crohn's disease.

Authors:  Johan Van Limbergen; David C Wilson; Jack Satsangi
Journal:  Annu Rev Genomics Hum Genet       Date:  2009       Impact factor: 8.929

View more
  2 in total

1.  Relationship between the IL23R SNPs and Crohn's Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study.

Authors:  Krzysztof Borecki; Iwona Zawada; Nermin Nusret Salkić; Beata Karakiewicz; Grażyna Adler
Journal:  Int J Environ Res Public Health       Date:  2019-05-02       Impact factor: 3.390

2.  Systematic meta-analyses and field synopsis of genetic and epigenetic studies in paediatric inflammatory bowel disease.

Authors:  Xue Li; Peige Song; Maria Timofeeva; Xiangrui Meng; Igor Rudan; Julian Little; Jack Satsangi; Harry Campbell; Evropi Theodoratou
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.